Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Amarin Announced New REDUCE-IT Data Showing Benefit Of VASCEPA/VAZKEPA In High-Risk Patients With A Recent Acute Coronary Syndrome Event

Amarin Corporation plc (NASDAQ: AMRN) today announced a new analysis from the VASCEPA/VAZKEPA (icosapent ethyl) cardiovascular outcomes REDUCE-IT study showing the effectiveness of VASCEPA®/VAZKEPA® in patients with recent acute coronary syndrome (<12 months before randomization).

AMRN

Read More

89bio Data Showed Pegozafermin Treatment Was Found To Be Effective In Reducing Triglycerides And Other Atherogenic Lipids In Patients With SHTG, Regardless Of Their Background Lipid-modifying Therapy

89bio, Inc. (Nasdaq: ETNB) today announced the presentation of additional data from the Phase 2 ENTRIGUE trial of pegozafermin in patients with severe hypertriglyceridemia (SHTG) at the American College of Cardiology's 72nd Annual Scientific Session & Expo Together with World Congress of Cardiology (ACC.23/WCC).

ETNB